|
 
- 积分
- 414
- 威望
- 414
- 包包
- 645
|
本帖最后由 细胞海洋 于 2014-1-4 09:43 编辑
1 c$ ?1 E) s( `4 t2 T) x3 I( b% J5 S6 g0 K X% H/ ]3 A
Molecular therapies$ ~6 ^6 \4 n3 F
Dr. Zoltán Balajthy, Dr. János Aradi, Dr. Zoltán Balajthy, Dr. Éva Csősz, Dr. Beáta Scholtz, Dr. István Szatmári, Dr. József Tőzsér, Dr. Tamás Varga (2011)
* k8 v, n% V: P3 J
' e- Q( h4 u: I: L% c. U, i5 QUniversity of Debrecen% l7 t% Z! Z' c: Y; H# J
Copyright © 2011 The project is funded by the European Union and co-financed by the European Social Fund., Manuscript completed: 17 November 2011
! n; S' y* v- _4 n2 h& f$ {$ q( W
$ v) a8 M. U0 l9 }) V- f
6 q) S8 R( R3 M' c% b
Index4 |6 G+ @" s7 V
1. 1. Functional Genomics) i7 o8 @$ q: Y. F7 E+ _' }7 @$ d5 |2 Y
1.1 Definitions
1 E& g# Y0 h4 D q" ^# F1.2 About diseases
. `5 B" s8 Y5 P. |3 v* W1.3 Approaches to understanding disease mechanisms
8 p4 c8 i# k7 L: E1 Q1.3.1 Gene expression is regulated in several basic ways" L# T4 S8 Y/ @
1.3.2 Microarrays: functional genomics in cancer research2 ^$ Y. k- M) V# c {3 j! s) S
1.3.3 A Variety of Genetic Alterations Underlie Developmental Abnormalities and Disease
# U. r4 ]+ P5 K1.3.4 Genomic microarrays
2 R" v5 j' q7 N$ y, w+ }2 A& {2. 2. Recombinant proteins
( r: s' M9 M, d* I" [& R( L! q2.1 Overview: Protein pharmaceuticals
# B: O3 P" B8 t- s: z2.2 Cell-free systems: In vitro transcription and translation
. y9 h/ d3 d @. J/ L, G2.3 Recombinant protein expression in isolated cells (cell culture)- f+ r9 v- `( C% }; S" p
2.4 Non-prokaryotic expression systems
' P) ]/ g# `* ` k0 E7 l2.4.1 Cloning in Pichia pastoris% N& k/ e4 z# A0 y
2.4.2 Baculovirus mediated protein expression in insect cells' _% j* E0 N: X3 O; c7 w0 c4 _9 f
2.4.3 Mammalian expression systems8 h. B1 D% ^% v1 Z0 l2 q
2.5 Purification of recombinant proteins3 w' A' G3 [5 d2 r
3. 3. Gene Therapy: Vectors and Strategies.
* ?2 P2 w! o9 L h8 H* k: r/ G3.1 Vectors for Gene Therapy
; k/ w2 @ p* L& Y" M, ^3.2. Types of gene transfer, vectors for gene therapy. F, ^" c3 J! |. q9 N. x, D
3.3. General gene therapy strategies0 z$ E/ {! K3 n, V" I$ u; Y
3.4. Human gene therapy; R* d/ c/ P& L9 ~0 n8 s
4. 4. Protein replacement therapies.
( b1 y l8 e, S& e) y z& S" p5. 5. Recombinant antibodies and the phage display technology
, Z# Z7 ^* z# D6 B* | B8 e5.1. Introduction
3 b$ L/ @% x+ `5 @* _( K5.1.1. The structure of antibodies and their production in the body; v) o6 q2 `1 t
5.1.2. Antigen-antibody binding# D- t6 ?9 u, D k |+ {3 V2 @0 I F8 h
5.2. The production of therapeutic antibodies
% d, K- N- J! w5 j5.2.1. The production of antibodies in hybridoma cells.
7 s1 {; o# Q2 L5.2.2. Humanized antibodies
6 ^% Y- f5 S9 Y% n. J. i5.2.3. Production of human antibodies
( s" n, e; P% M8 n0 v/ [4 F5.3. Generation of antibodies by phage display
' V' C6 D( P5 e$ I' R5.3.1. The phage display technology
' C( P. V8 y D+ c5.3.2. Generation of phage libraries
$ G+ b- H) I& Q u1 Z5.4. Administration of therapeutic antibodies) \3 m" }. E" ~* ~2 Y" I; w" P
6. 6. Anti-cytokine Therapy (sepsis).
$ b' H `- b( y9 G" f7 j8 |6.1. The consequences of developing inflammation) R, M8 ?$ Z. I* `! M
6.2. Development of Inflammatory Response: Synthesis of Lipid Mediators
8 L0 c5 ?/ R, o( f/ P& e% {6.3. Role of the Liver in Maintenance of Homeostasis: Acute Phase Response2 v* O B6 @, ^
6.4. Time-Course of the Inflammatory Response During Sepsis
+ S% B4 I! ^4 U1 O' Z, l# b/ p9 r% z0 o7. 7. Animal models and transgenesis in biotechnology
* D1 e: E# x* @9 z2 m, j _8 r8. 8. Embryonic and adult stem cells in regenerative medicine I.1 k6 b# x0 j; i/ Q/ k& n/ a a' E) t
8.1 Embryonic stem cells
' }5 @2 a. N' l, K' Q5 l; _) V+ T8.2 Somatic cell reprogramming into pluripotent stem cells
8 W: h' ]& |. _$ g3 K8.3 Adult stem cells2 {; A9 z" h1 X2 Z7 N4 F k! a
9. 9. Embryonic and adult stem cells in regenerative medicine II.
" d8 ] F/ P' C# v i0 [9.1 Pluripotent stem cells for regenerative medicine
' K9 _# v7 T! X. E9 P9.2 Clinical application of stem cells3 l9 C4 f! s) S b/ _
9.3 Stem cell therapy to cure various diseases4 k- H) V- R5 n
10. 10. Cell Cycle and Cancer Therapy, p53 I.. k* q) W& K- J/ E
10.1 Cell Cycle
. ~/ y$ @) Q9 B, {# o# J. }# D8 b( q$ z10.2. Mitogenic Signaling in Eukaryotic Cell Controls the Rate of Cell Division4 i) e8 ^7 a2 o* d& K
10.3. Biochemical Events of Cell-cycle – in M Phase
- S0 t) @1 D& D6 K; q10.4. Protooncogenes4 M, z8 W6 }# Q2 O6 V6 L
10.5. ErbB/HER Receptors# {! S; V0 D9 X0 j# P
10.6. Therapeutic targets
3 r- V% ?$ N: N11. 11. Cell Cycle and Cancer Therapy, p53 II." D3 d$ Z5 N1 j. j3 w
11.1. Tumor Suppressor Genes and p53
9 U/ s" j: A# `: ~* U+ {" r11.2. Biochemical Pathways of Apoptosis and its Therapeutic Utilization
! w* N+ a5 p) i2 `12. 12. Gene Silencing Technologies.7 I& }6 Z$ o* I
12.1 Introduction* h" u$ o P y, y+ z8 G
12.2 Action of antisense oligonucleotides* O B/ k+ N9 U8 P- T/ j
12.3 Chemical modifications of gene silencing oligonucleotides; general considerations
4 @6 G& H7 J, ?& D12.4 Inhibition of transcription by triple helix forming oligonucleotides/ B1 s: j5 C2 p/ T; I
12.5 Gene silencing by ribozymes
2 W( P; S: ~8 f8 P7 I* U12.6 Gene silencing with short RNA fragments7 J5 G1 w% w; U1 {0 p2 |% \
12.7 Important final note
. F4 y8 J6 m1 ]: |. D
% Y [# I$ {% N" f/ u[hide][/hide] |
附件: 你需要登录才可以下载或查看附件。没有帐号？注册
-
总评分: 威望 + 5
包包 + 20
查看全部评分
|
发表于 2014-1-3 16:18
